within Pharmacolibrary.Drugs.ATC.L;

model L03AX13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Glatiramer acetate is an immunomodulatory drug used primarily for the treatment of relapsing-remitting multiple sclerosis (RRMS). It is a synthetic mixture of polypeptides composed of four amino acids and works by modifying immune processes thought to be involved in MS. It is still approved and used today for this indication.</p><h4>Pharmacokinetics</h4><p>No classical pharmacokinetic parameters are available in the literature for glatiramer acetate, as it is rapidly degraded locally after subcutaneous administration and plasma concentrations are undetectable. Data represent known clinical use in adults with multiple sclerosis.</p><h4>References</h4><ol><li><p>McKeage, K (2015). Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. <i>CNS drugs</i> 29(5) 425–432. DOI:<a href=&quot;https://doi.org/10.1007/s40263-015-0245-z&quot;>10.1007/s40263-015-0245-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25906331/&quot;>https://pubmed.ncbi.nlm.nih.gov/25906331</a></p></li><li><p>Scott, LJ (2013). Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. <i>CNS drugs</i> 27(11) 971–988. DOI:<a href=&quot;https://doi.org/10.1007/s40263-013-0117-3&quot;>10.1007/s40263-013-0117-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24129744/&quot;>https://pubmed.ncbi.nlm.nih.gov/24129744</a></p></li><li><p>Cohen, J, et al., &amp; Barkhof, F (2015). Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA neurology</i> 72(12) 1433–1441. DOI:<a href=&quot;https://doi.org/10.1001/jamaneurol.2015.2154&quot;>10.1001/jamaneurol.2015.2154</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26458034/&quot;>https://pubmed.ncbi.nlm.nih.gov/26458034</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AX13;
